Anti-inflammatory and gut microbiota modulatory effects of polysaccharides from Fuzhuan brick tea on colitis in mice induced by dextran sulfate sodium

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Crude polysaccharides from Fuzhuan brick tea (CFBTPS) and FBTPS-3 could promote the growth of beneficial bacteria, maintain the stability of the intestinal barrier and exhibit good anti-inflammatory activity against DSS-induced colitis in mice.

Abstract

In this study, the effects of crude Fuzhuan brick tea polysaccharides (CFBTPS) and their purified fraction (FBTPS-3) on colitis induced by dextran sulfate sodium (DSS) in mice were investigated. Both CFBTPS and FBTPS-3 exhibited intestinal anti-inflammatory activities, including restoring body weight, colon length and solid fecal weight, and decreasing the disease activity index score in mice. Moreover, the expression of lipocalin-2 in colitis could be significantly reduced. The inflammatory cytokines (IL-6, IL-1β, IFN-γ and TNF-α) and lipopolysaccharides in the serum and the expression of inflammation-related mRNA in the colon tissue were decreased. Both CFBTPS and FBTPS-3 could increase tight junction proteins (Occludin, Claudin-1 and ZO-1), promoting the intestinal barrier function. For gut microbiota, DSS treatment resulted in abnormal proliferation of Bifidobacteria, while FBTPS-3 could restore this disorder to a certain extent. In addition, FBPTS-3 promoted the growth of probiotics such as Bacteroides, Parasutterella and Collinsella. Both CFBTPS and FBTPS-3 could attenuate colitis; what's more, FBTPS-3 exhibited a better anti-inflammatory effect than CFBTPS.

Related collections

Most cited references 68

Record: found
Abstract: found
Article: not found

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.

Siew C. Ng, Hai Yun Shi, Nima Hamidi … (2017)

Inflammatory bowel disease is a global disease in the 21st century. We aimed to assess the changing incidence and prevalence of inflammatory bowel disease around the world.

0 comments Cited 1571 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases

Daniela Parada Venegas, Marjorie K. De la Fuente, Glauben Landskron … (2019)

Ulcerative colitis (UC) and Crohn's disease (CD), collectively known as Inflammatory Bowel Diseases (IBD), are caused by a complex interplay between genetic, immunologic, microbial and environmental factors. Dysbiosis of the gut microbiome is increasingly considered to be causatively related to IBD and is strongly affected by components of a Western life style. Bacteria that ferment fibers and produce short chain fatty acids (SCFAs) are typically reduced in mucosa and feces of patients with IBD, as compared to healthy individuals. SCFAs, such as acetate, propionate and butyrate, are important metabolites in maintaining intestinal homeostasis. Several studies have indeed shown that fecal SCFAs levels are reduced in active IBD. SCFAs are an important fuel for intestinal epithelial cells and are known to strengthen the gut barrier function. Recent findings, however, show that SCFAs, and in particular butyrate, also have important immunomodulatory functions. Absorption of SCFAs is facilitated by substrate transporters like MCT1 and SMCT1 to promote cellular metabolism. Moreover, SCFAs may signal through cell surface G-protein coupled receptors (GPCRs), like GPR41, GPR43, and GPR109A, to activate signaling cascades that control immune functions. Transgenic mouse models support the key role of these GPCRs in controlling intestinal inflammation. Here, we present an overview of microbial SCFAs production and their effects on the intestinal mucosa with specific emphasis on their relevance for IBD. Moreover, we discuss the therapeutic potential of SCFAs for IBD, either applied directly or by stimulating SCFAs-producing bacteria through pre- or probiotic approaches.

0 comments Cited 1128 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.

Natalie Molodecky, Ing Soon, Doreen M Rabi … (2012)

We conducted a systematic review to determine changes in the worldwide incidence and prevalence of ulcerative colitis (UC) and Crohn's disease (CD) in different regions and with time. We performed a systematic literature search of MEDLINE (1950-2010; 8103 citations) and EMBASE (1980-2010; 4975 citations) to identify studies that were population based, included data that could be used to calculate incidence and prevalence, and reported separate data on UC and/or CD in full manuscripts (n = 260). We evaluated data from 167 studies from Europe (1930-2008), 52 studies from Asia and the Middle East (1950-2008), and 27 studies from North America (1920-2004). Maps were used to present worldwide differences in the incidence and prevalence of inflammatory bowel diseases (IBDs); time trends were determined using joinpoint regression. The highest annual incidence of UC was 24.3 per 100,000 person-years in Europe, 6.3 per 100,000 person-years in Asia and the Middle East, and 19.2 per 100,000 person-years in North America. The highest annual incidence of CD was 12.7 per 100,000 person-years in Europe, 5.0 person-years in Asia and the Middle East, and 20.2 per 100,000 person-years in North America. The highest reported prevalence values for IBD were in Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 persons) and North America (UC, 249 per 100,000 persons; CD, 319 per 100,000 persons). In time-trend analyses, 75% of CD studies and 60% of UC studies had an increasing incidence of statistical significance (P < .05). Although there are few epidemiologic data from developing countries, the incidence and prevalence of IBD are increasing with time and in different regions around the world, indicating its emergence as a global disease. Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.